Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer

[1]  M. Köbel,et al.  The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma , 2012, Clinical & Experimental Metastasis.

[2]  Maureen A. Smith,et al.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Jirström,et al.  Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer , 2011, British Journal of Cancer.

[4]  Tin-Lap Lee,et al.  Methylation of an intronic region regulates miR-199a in testicular tumor malignancy , 2011, Oncogene.

[5]  J. Wilkins,et al.  Requirement of Podocalyxin in TGF-Beta Induced Epithelial Mesenchymal Transition , 2011, PloS one.

[6]  L. Påhlman,et al.  Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer , 2011, British Journal of Cancer.

[7]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[8]  D. Ryan,et al.  American Society of Clinical Oncology 2010 colorectal update , 2010, Expert review of anticancer therapy.

[9]  C. Shun,et al.  Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. , 2010, The American journal of pathology.

[10]  K. Jirström,et al.  High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer , 2009, British Journal of Cancer.

[11]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[12]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[13]  C. Roskelley,et al.  The CD34-Related Molecule Podocalyxin Is a Potent Inducer of Microvillus Formation , 2007, PloS one.

[14]  F. Prall.  Tumour budding in colorectal carcinoma , 2007, Histopathology.

[15]  J. Witte,et al.  Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. , 2006, Human molecular genetics.

[16]  Gang Wu,et al.  Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. , 2006, Biochemical and biophysical research communications.

[17]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[18]  B. Tilton,et al.  Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. , 2005, Molecular and cellular probes.

[19]  V. Thorsson,et al.  Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells*S , 2004, Molecular & Cellular Proteomics.

[20]  J. Overgaard,et al.  Quantitative PCR – new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real‐time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization , 2004, Scandinavian journal of clinical and laboratory investigation.

[21]  D. Huntsman,et al.  Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression , 2004, Cancer Research.

[22]  S. Loening,et al.  Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. , 2002, European urology.

[23]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[24]  M. Farquhar,et al.  Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells. , 2000, Molecular biology of the cell.

[25]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[26]  M. Mann,et al.  Thrombomucin, a Novel Cell Surface Protein that Defines Thrombocytes and Multipotent Hematopoietic Progenitors , 1997, The Journal of cell biology.

[27]  K. Hase,et al.  Prognostic value of tumor “budding” in patients with colorectal cancer , 1993, Diseases of the colon and rectum.

[28]  G. Dekan,et al.  Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells , 1986, The Journal of cell biology.

[29]  M. Smith.  Immunohistochemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome , 2012 .

[30]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[31]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .